Emerging data now suggests that the combining TKIs with either BCL-2/BCL-XL or pan-BCL-2 inhibitors can selectively enhance cytotoxicity and thus eradicate CML stem/progenitor cells (95, 99, 100). This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.